Sleep Medicine
Volume 9, Issue 6 , Pages 603-614 , August 2008

Cytokines and pathological sleep

  • Fotis Kapsimalis

      Affiliations

    • Pulmonology Department, Sleep Laboratory, Henry Dunant Hospital, Athens, Greece
    • Corresponding Author InformationCorresponding author.
    • ,
  • Maria Basta

      Affiliations

    • Center for Sleep Disorders Medicine, Department of Psychiatry, Penn state College of Medicine, Hershey, PA, USA
    • ,
  • George Varouchakis

      Affiliations

    • Pulmonology Department, Sleep Laboratory, Henry Dunant Hospital, Athens, Greece
    • ,
  • Konstantinos Gourgoulianis

      Affiliations

    • Pulmonology Department, Medical School, University of Thessaly, Larissa, Greece
    • ,
  • Alexandros Vgontzas

      Affiliations

    • Center for Sleep Disorders Medicine, Department of Psychiatry, Penn state College of Medicine, Hershey, PA, USA
    • ,
  • Meir Kryger

      Affiliations

    • Sleep Medicine, Research and Education, Gaylord Hospital, Wallingford, CT, USA

Received 8 May 2007 ,Revised 30 July 2007 ,Accepted 19 August 2007.

References 

  1. Kapsimalis F, Richardson G, Opp M, Kryger M. Cytokines and normal sleep. Curr Opin Pulm Med. 2005;11(6):481–484
  2. Blalock JE. A molecular basis for bidirectional communication between the immune and neuroendocrine system. Physiol Rev. 1989;69:1–32
  3. Moldofsky H. Central nervous system and peripheral immune functions and the sleep–wake system. J Psychiatr Neurosci. 1994;19(5):368–374
  4. Dinarello CA. The biology of interleukin-1. FASEB J. 1988;2:108–113
  5. Ohayon MM, Caulet M, Phillip P, Guilleminault C, Priest RAG. How sleep and mental disorders are related to complaints of daytime sleepiness. Arch Intern Med. 1997;157:2645–2652
  6. American Sleep Disorders Association Diagnostic Classification Steering Committee. International classification of sleep disorders. Diagnostic and coding manual. Rochester: American Sleep Disorders Association; 1990.
  7. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82:1313–1316
  8. Vgontzas AN, Bixler EO, Tan TL, Kantner D, Martin LF, Kales A. Obesity without sleep apnea is associated with daytime sleepiness. Arch Intern Med. 1998;158:1333–1337
  9. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am. 2003;32(4):869–894
  10. Fantuzzi G. Adipose tissue, adipokines and inflammation. J Allergy Clin Immunol. 2005;115(5):911–919
  11. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc. 2004;79(8):1036–1046
  12. Krueger JM, Majide JA. Humoral links between sleep and the immune system. Ann NY Acad Sci. 2003;992:9–20
  13. Lue FA, Bail M, Jepthtah-Oshola J, Jepthtah-Ochola J, Carayanniotis K, Gorczynski R, et al. Sleep and cerebrospinal fluid interleukin-1 activity in the cat. Int J Neurosci. 1988;42:179–183
  14. Dickstein JB, Moldofsky H, Lue FA, Hay JB. Intracerecroventricular injection of TNF-a promotes sleep and is recovered in cervical lymph. Am J Physiol. 1999;276:R1018–R1022
  15. Krueger JM. Somnogenic activity of immune response modifiers. TIPS. 1990;11:122–126
  16. Obal F, Krueger JM. Biochemical regulation of non-rapid eye movement sleep. Front Biosci. 2003;520–550
  17. Moldofsky H, Lue FA, Eisen J, Keystone E, Corczynski RM. The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med. 1986;48:309–318
  18. Covelli V, Massari F, Fallarca C, Fallacara C, Munno I, Jirillo E, et al Interleukin-1 beta and beta endorphin circadian rhythms are inversely related in normal and stress-altered sleep. Int J Neurosci. 1992;63:299–305
  19. Irwin M, Thompson J, Miller C, Gillin JC, Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans. J Clin Endocrinol Metabol. 1999;84:1979–1985
  20. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review an analysis of alternative mechanisms. Life Sci. 1995;57:1011–1026
  21. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1 beta mRNA in the brain of rats in response to systemic IL-1 beta. J Neurosci. 1998;18:2247–2253
  22. Chen L, Duricka D, Nelson S, Mukherjee S, Bohnet SG, Taishi P, et al. Influenza virus-induced sleep responses in mice with targeted disruptions in neuronal or inducible nitric oxide synthases. J Appl Physiol. 2004;97:17–28
  23. Dinarello CA. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int Suppl. 1992;38:S68–S77
  24. Steiger A. Eating and sleeping-their relationship to ghrelin and leptin. Am J Physiol Regul Integr Comp Physiol. 2004;287(5):R1031–R1032
  25. Obal F, Alt J, Taishi P, Gardi J, Krueger JM. Sleep in mice with non-functional growth-hormone-releasing hormone receptors. Am J Physiol Regul Integr Comp Physiol. 2003;284:R131–R139
  26. Weikel JC, Wichniak A, Ising M, Brunner H, Friess E, Held K, et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab. 2003;284:E407–E415
  27. Szentirmai E, Kapas L, Krueger JM. Ghrelin microinjection into forebrain sites induces wakefulness and feeding in rats. Am J Physiol Regul Integr Comp Physiol. 2007;292:R575–R585
  28. Steiger A. Ghrelin and sleep–wake regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R573–R574
  29. Szentirmai E, Krueger JM. Obestatin alters sleep in rats. Neurosci Lett. 2006;404:222–226
  30. Sinton CM, Fitch TE, Gershenfeld HK. The effects of leptin on REM sleep and slow wave delta in rats are reversed by food deprivation. J Sleep Res. 1999;8(3):197–203
  31. Dzaja A, Dalal MA, Himmerich H, Uhr M, Pollmacher T, Schuld A. Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. Am J Physiol Endocrinol Metab. 2004;286:E963–E967
  32. Mullington JM, Chan JL, Van Dongen HP, Szuba MP, Samaras J, Price NJ, et al. Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol. 2003;15:851–854
  33. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced sleep leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1(3):e62;[Epub 2004 Dec. 7]
  34. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type II diabetes. J Appl Physiol. 2005;(99):2008–2019
  35. Spiegel K, Tasali E, Pevev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141:846–850
  36. Dinarello CA, Cannon JG, Wolff SM. New concepts on the pathogenesis of fever. Rev Infect Dis. 1988;10:168–189
  37. Dinarello CA, Krueger JM. Induction of interleulin-1 by synthetic and naturally occurring muramyl peptides. Fed Proc. 1986;45:2545–2548
  38. Schuld A, Haack M, Hinze-Selch D, Mullington J, Pollmacher T. Experimental studies on the interaction between sleep and immune system in humans. Psychother Psychosom Med Psychol. 2005;55(1):29–35
  39. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behaviour. Brain Behav Immun. 2003;S1:S112–S118
  40. Shoham S, Davenne D, Caby AB, Dinarello CA, Krueger JM. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol. 1987;253:R142–R149
  41. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112:321S–329S
  42. Hirsch M, Carlander B, Verge M, Tafti M, Anaya JM, Billiard M, et al. Objective and subjective sleep disturbances in patients with RA: a reappraisal. Arthritis Rheum. 1994;37:41–49
  43. Darko DF, Miller JC, Gallen C, White J, Koziol J, Brown SJ, et al. Sleep electroencephalogram delta frequency amplitude, night plasma levels of TNF-alpha, and human immunodeficiency virus infection. Proc Natl Acad Sci USA. 1995;92:12080–12084
  44. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology(Oxford). 1999;38(Suppl 2):3–7
  45. Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis. 2004;63:88–90
  46. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. Ciba Found Symp. 1993;173:262–271
  47. Vgontzas A. The diagnosis and treatment of chronic insomnia in adults. Sleep. 2005;28(9):1047–1048
  48. Moldofsky H, Lue FA, Davidson JR, Corczynski R. Effects of sleep deprivation on human immune functions. FASEB J. 1989;3:1972–1977
  49. Opp MR, Krueger JM. Anti-inteleukin-1b reduces sleep and sleep rebound after sleep deprivation in rats. Am J Physiol. 1994;266:R688–R695
  50. Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, et al. Interleukin-6 serum levels in healthy persons correspond to the sleep–wake cycle. Clin Invest. 1994;72:315
  51. Redwine L, Hauger J, Gillin C, Irwin M. Effects of sleep and sleep deprivation on Interleukin-6, growth hormone, cortisol and melatonin in humans. J Clin Endocrinol Metab. 2000;85:3597–3603
  52. Vgontzas AN, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999;84:2603–2607
  53. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follet H, Kales A, et al. Adverse effects of modest sleep restriction on sleepiness, performance and inflammatory cytokines. J Clin Endocrinol Metab. 2004;89(5):2119–2126
  54. Vgontzas AN, Pejovic S, Zoumakis E, Lin HM, Bixler EO, Basta M, et al. Daytime napping after sleep loss decreases sleepiness, improves performance and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab. 2007;292:E252–E261
  55. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous system functions in healthy men. J Clin Endocrinol Metab. 1998;83:1573–1579
  56. Morrow JD, Opp MR. Sleep–wake behavior and responses of interleukin-6-deficient mice to sleep deprivation. Brain Behav Immun. 2005;19:28–39
  57. Benca RM, Obermayer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders: a meta analysis. Arch Gen Psychiatry. 1992;49:651–668
  58. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun. 2002;16:503–512
  59. Alberti A, Sarchielli P, Gallinella E, Floridi A, Floridi A, Mazzotta G, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res. 2003;12:305–311
  60. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab. 2000;85:1151–1158
  61. Minogushi K, Tazaki T, Yokoe T, Minogushi H, Watanabe Y, Yamamoto M, et al. Elevated production of Tumor Necrosis Factor-A by monocytes in patients with obstructive sleep apnea syndrome. Chest. 2004;126:1473–1479
  62. Mills PJ, Dimsdale JE. Sleep apnea: a model for studying cytokines, sleep and sleep disruption. Brain Behav Immun. 2004;18:298–303
  63. Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakynthinos S, Roussos C. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med. 2002;166:1572–1578
  64. Fried SK, Bunklin DA, Greenberg AS. Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–850
  65. Ciftci TU, Kozturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine. 2004;28:87–91
  66. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med. 2003;254:32–44
  67. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-Bueno A, Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes and depression. J Clin Endocrinol Metab. 2005;90:4510–4515
  68. Resta O, Foschino-Barbaro MP, Legari G, Talamo S, Bonfitto P, Palumbo A, et al. Sleep-related breathing disorders, loud snoring, and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord. 2001;25:669–675
  69. Vgontzas A, Legro R, Bixler E, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obsytructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86:517–520
  70. Fogel R, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1175–1178
  71. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med. 2002;3:401–404
  72. Vgontzas A, Chroussos G. Sleep-disordered breathing, sleepiness, and insulin resistance: is the latter a consequence, a pathogenetic factor or both?. Sleep Med. 2001;3:389–391
  73. Tasali E, Van Cauter E, Ehrmann DA. Relationship between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):36–42
  74. Vgontzas A, Trakada G, Bixler E, Lin HM, Pejovic S, Zoumakis E, et al. Plasma IL-6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism. 2006;55:1076–1082
  75. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148–1150
  76. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–516
  77. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419–428
  78. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-A and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–2153
  79. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000;148:209–214
  80. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: the effects of an early invasive or noninvasive strategy. JAMA. 2001;2107–2113
  81. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772
  82. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–194
  83. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116:1813–1822
  84. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154–1159
  85. Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757–1762
  86. Andreozzi F, Laratta E, Cardellini M, Marini MA, Lauro R, Hribal ML, et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian–Caucasian nondiabetic subjects. Diabetes. 2006;55:2021–2024
  87. Schulz R, Hummel C, Heinemann S, Seeger W, Grimmnger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med. 2002;165:67–70
  88. Imigawa S, Yamaguchi Y, Higushi M, Neichi T, Hasegawa Y, Mukai HY, et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea–hypopnea syndrome. Blood. 2001;98:1255–1257
  89. Gozal D, Lipton AJ, Jones KL. Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea syndrome. Sleep. 2002;25:59–65
  90. Lavie L, Kraiczi H, Hefetz A, Ghandour H, Perelman A, Hedner J, et al. Plasma VEGF in sleep apnea syndrome: effects of nCPAP treatment. Am J Respir Crit Care Med. 2002;165:1624–1628
  91. Cherniack N. Inflammatory ideas about Sleep apnea. Respiration. 2004;71:20–21
  92. Imagawa S, Yamagutsi Y, Ogawa K, Obara N, Suzuki N, Yamamoto M, et al. Interleukin-6 and Tumor Necrosis Factor-A in patients with obstructive sleep apnea–hypopnea syndrome. Respiration. 2004;71:24–29
  93. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P Vela-Bueno A, Kales A, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumour necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51(7):887–892
  94. Ip MMS, Lam B, Ng MMT, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165:670–676
  95. Punjabi NM, Sorkin JD, Katzel L, Goldberg AP, Schwartz AP, Smith PL. Sleep-disordered breathing and insulin resistance in middle aged and overweight men. Am J Respir Crit Care Med. 2002;165:677–682
  96. Tasali E, Van Gauter M. Sleep disordered breathing and the current epidemic of obesity. Am J Respir Crit Care Med. 2002;165:562–563
  97. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005;9:211–224
  98. Ip MSM, Lam KSL, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest. 2000;118:580–586
  99. Chin K, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, et al. Changes in intraabdominal visceral fat and leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation. 1999;100:706–712
  100. Hatipoglu U, Rubistein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration. 2003;70:665–671
  101. Finck BN, Johnson RW. Tumor necrosis factor alpha regulates secretion of the adipocyte-derived cytokine, leptin. Microsc Res Tech. 2000;50:209–215
  102. Zhang XL, Yin KS, Mao H, Wang H, Yang Y. Serum adiponectin level in patients with obstructive sleep apnea–hypopnea syndrome. Chin Med J (Engl). 2004;117(1):1603–1606
  103. Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea–hypopnea syndrome. Respiration. 2006;73(1):73–77
  104. Makino S, Handa H, Suzukawa K, Fujiwara M, Nakamura M, Muraoka S, et al. Obstructive sleep apnoea, plasma adiponectin levels and insulin resistance. Clin Endocrinol. 2006;64:12–19
  105. Wolk R, Svatikova A, Nelson CA, Gami AS, Govender K, Winnicki M, et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone in sleep apnea. Obes Res. 2005;13(1):186–190
  106. Harsch IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, et al. Resistin levels in patients with obstructive sleep apnea syndrome – the link to subclinical inflammation?. Med Sci Monit. 2004;10(9):CR510–CR515
  107. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2005;289(4):E586–E590
  108. Yokoe T, Minogushi K, Matsuo H, Oda N, Minogushi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129–1134
  109. Arter JL, Chi DS, Girish M, Fitzerald SM, Guha B, Krishnaswamy G. Obstructive sleep apnea, inflammation and cardiopulmonary disease. Front Biosci. 2004;9:2892–2900
  110. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med. 1996;153:1080–1086
  111. Reid MB, Lannergen J, Westerblad H. Respiratory and limb muscle weakness induced by tumour necrosis factor alpha. Am J Respir Crit Care Med. 2002;166:479–484
  112. Harsch IA, Wallaschofski H, Koebnick C, Schahin SP, Hahn EG, Ficker JH, et al. Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. Respiration. 2004;71:580–586
  113. Kataoka T, Enomoto F, Kim R, Yokoi H, Fujimori M, Ando I, et al. The effect of surgical treatment of obstructive sleep apnea syndrome on the plasma TNF-a levels. Tohoku J Exp Med. 2004;204:267–272
  114. Sabato R, Guido P, Salerno FG, Goldberg AP, Schwartz AP, Smith PL. Airway inflammation in patients affected by obstructive sleep apnea. Monaldi Arch Chest Dis. 2006;65:102–105
  115. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chroussos P. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumour necrosis factor-alpha antagonist. J Clin Endocrinol Metab. 2004;89(9):4409–4413
  116. Vgontzas AN, Zoumakis M, Bixler EO, Lin HM, Prolo P, Vela-Bueno A, et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab. 2003;88:2087–2095
  117. Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcohol Clin Exp Res. 1998;22:1864–1871
  118. Drummond SP, Gillin JC, Smith TL, DeModena A. The sleep of abstinent pure primary alcoholic patients: natural history and relationship to relapse. Alcohol Clin Exp Res. 1998;22:1796–1802
  119. Irwin M, Rinetti G, Redwine L, Motivala S, Dang J, Ehlers C. Nocturnal proinflammatory cytokine-associated sleep disturbances in abstinent African American alcoholics. Brain Behav Immun. 2004;18(4):349–360
  120. Anisman H, Merali Z. Cytokines, stress and depressive illness. Brain Behav Immun. 2002;16:513–524
  121. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35:2–11
  122. Sakurai T. Role of orexins and orexin receptors in central regulation of feeding behaviour and energy homeostasis. CNS Neurol Disord Drug Targets. 2006;5:313–325
  123. Himmerich H, Beitinger PA, Fulda S, Griegling I, Epplen JT, Dahmen N. Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Arch Intern Med. 2006;166:1739–1743
  124. Okun ML, Giese S, Einen M, Mignot E, Coussons-Read ME. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun. 2004;18(4):326–332
  125. Wieczorec S, Gencik M, Rujescu D, Tonn P, Wehrle R, Linseisen J, et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens. 2003;61(6):437–442
  126. Wieczorec S, Dahmen N, Kasten M, Epplen JT, Gencik M. A rare form of narcolepsy (HLA-DR2−) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. Psychiatr Genet. 2004;14:47–51

PII: S1389-9457(07)00322-X

doi: 10.1016/j.sleep.2007.08.019

Sleep Medicine
Volume 9, Issue 6 , Pages 603-614 , August 2008

Article Tools